Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities

Abstract

BackgroundMultiple myeloma (MM) is a highly heterogeneous disease with enormously variable outcomes. It remains to be a major challenge to conduct a more precise estimation of the survival of MM patients. The existing stratifications attached less importance to the prognostic significance of comorbidities. In the present study, we aimed to develop and validate a novel and simple prognostic stratification integrating tumor burden and comorbidities measured by HCT-CI.MethodWe retrospectively enrolled 385 consecutive newly diagnosed multiple myeloma (NDMM) patients in Xijing Hospital from January 2013 to December 2020. The cohort between January 2016 and December 2020 was selected as development cohort (N = 233), and the cohort between January 2013 and December 2015 was determined as validation cohort (N = 152). By using LASSO analysis and univariate and multivariable Cox regression analyses, we developed the MM-BHAP model in the way of nomogram composed of β2-MG, HCT-CI, ALB, and PBPC. We internally and externally validated the MM-BHAP model and compared it with ISS stage and R-ISS stage.ResultsThe MM-BHAP model was superior to the ISS stage and partially better than the R-ISS stage according to time-dependent AUC, time-dependent C-index, DCA, IDI, and continuous NRI analyses. In predicting OS, only the MM-BHAP stratification clearly divided patients into three groups while both the ISS stage and R-ISS stage had poor classifications in patients with stage I and stage II. Moreover, the MM-BHAP stratification and the R-ISS stage performed well in predicting PFS, but not for the ISS stage. Besides, the MM-BHAP model was also applied to the patients with age ≤65 or age >65 and with or without HRCA and could enhance R-ISS or ISS classifications.ConclusionsOur study offered a novel simple MM-BHAP stratification containing tumor burden and comorbidities to predict outcomes in the real-world unselected NDMM population.

The Expression of Serum lncRNA MIR17HG in Patients with Multiple Myeloma and Its Clinical Significance

“…Collectively, the abovementioned fndings and evidence make it plausible to conclude that serum MIR17HG level >1.485 could evaluate the accuracy of MM diagnosis. MM is a highly heterogeneous disease, and the prognosis of MM patients varies greatly [28]. Accordingly, the accurate estimation of the survival time of MM patients remains a major challenge [29].…”

Prognostic Implications of Endothelial Activation and Stress Index (Easix) in Multiple Myeloma Patients

“…Despite the availability of improved and novel biomarkers for predicting MM patients' overall prognosis, currently, there is insufficient data to use predictive markers to assess initial MM treatment, intensify therapy for high-risk MM, or switch to an entirely alternative therapeutic strategy. (22) Even though MM is incurable, new therapies have significantly improved the median overall survival over time. However, even among patients with the same genetic background, there is a significant difference in outcome, with survival ranging from a few months to more than ten years.…”

“…Furthermore, the complexity and absence of standardization among these markers can result in unreliable results. (4).…”

A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis

“…Univariate Cox regression was utilized to analyze and evaluate the variables in the development cohort, and P<0.1 was used as the criterion for screening candidate variables. To prevent overfitting, we performed Lasso regression on the selected candidate variables ( 18 ). Considering the clinical practicality, we finally selected four variables for the construction of a new predictive model for PCNSL, and wholly evaluated the model by multivariate Cox regression analysis.…”